Clinical Core

临床核心

基本信息

项目摘要

Summary (Clinical Core) In speech-language or stroke rehabilitation literature, relatively little attention has been paid to threats to a study’s validity that relate to correct implementation of treatment, and also assessment, procedures. These threats can increase the chance of Type I or Type II error, or the additional error (“Type III”) of concluding significance or nonsignificance when in fact the tests or the treatments were not correctly implemented. Additionally, these threats can prevent causal inference. In the absence of fidelity monitoring, investigators are unable to confidently determine whether or not results (significant or insignificant) were caused by the targeted independent variable or due to other random factors introduced because the clinician “drifted” from the protocol, or “contaminated” the protocol by adding or omitting elements. Lack of attention to implementation, then, could be a contributor to the historically mixed results in aphasia treatment research emphasized by Project 1 and Project 2. Most of the aims proposed by Fridriksson, Hillis, Bonilha, Rorden, and Hickok require recruitment and retention of patients and collection of high quality data. High quality data necessitate that assessors use prescribed administration procedures and raters adhere to prescribed scoring procedures. Seven of twelve project aims rely upon treatment, and therapists that adhere to prescribed treatment procedures. The assumption of the investigators is that clinical staff functioning as assessors, raters, and/or therapists adhere to the study protocol. Efforts to optimize adherence to assessment and treatment procedures, referred to as assessment and treatment fidelity, are critical to the proposed projects. The Clinical Core will coordinate and activities designed to optimize fidelity, thereby guarding against threats to validity and improving the power to detect effects for nearly every aim proposed. To guard against threats to validity stemming from selection bias, attrition, or missing data points, the Clinical Core will conduct training and monitoring activities related to recruitment, retention, and data collection and management. To guard against threats to validity stemming from drift, cross-contamination, clinician-to- clinician variability, or unblinding, the Clinical Core will conduct extensive training, initial and throughout the study, and monitoring activities that will ensure that there is standardized training for all clinical staff, that assessment and treatment was delivered as intended, and that there is evidence that treatment was received as planned. As far as we can tell, these will be among the first studies in stroke or aphasia rehabilitation to: (1) incorporate multiple-tier training programs for all study member staff, (2) monitor treatment fidelity through several complementary methods, and (3) monitor assessment fidelity via adoption of established treatment fidelity guidelines. Finally, the Clinical Core will also support the Projects by scoring behavioral data, both for reliability measures and for blinded measures of outcome. Thus, the main goals of the Core are training the study team, scoring and management of behavioral data, and optimizing adherence to the protocols.
总结(临床核心) 在言语语言或中风康复文献中,相对较少关注对患者的威胁。 研究有效性与正确实施治疗以及评估程序有关。这些 威胁可能会增加I型或II型错误的机会,或者是得出结论的额外错误(“III型”) 当实际上测试或治疗没有正确实施时,显着或不显着。 此外,这些威胁可以阻止因果推理。在没有忠诚度监测的情况下,调查人员 无法自信地确定结果(显著或不显著)是否由目标 独立变量或由于临床医生“偏离” 协议,或通过添加或省略元素“污染”协议。缺乏对执行的重视, 那么,可能是失语症治疗研究中历史上混合结果的贡献者, 项目1和项目2。Fridriksson,Hillis,Bonilha,Rorden和Hickok提出的大多数目标都要求 招募和留住患者以及收集高质量数据。高质量的数据需要 评估员使用规定的管理程序,评分员遵守规定的评分程序。 十二个项目目标中的七个依赖于治疗,以及坚持规定治疗的治疗师 程序.研究者的假设是,临床工作人员作为评估者、评级者和/或 治疗师遵守研究方案。努力优化对评估和治疗的坚持 被称为评估和处理保真度的程序对拟议项目至关重要。临床 核心将协调和活动,旨在优化保真度,从而防止威胁的有效性和 提高了对几乎每一个提出的目标的检测效果的能力。 为了防止由于选择偏倚、损耗或缺失数据点而对有效性造成的威胁, 核心部门将开展与招聘、留用和数据收集相关的培训和监测活动, 管理为了防止漂移、交叉污染、临床医生对 临床医师变异性或揭盲,临床核心将进行广泛的培训,初始和整个 研究和监测活动,以确保所有临床工作人员得到标准化培训, 评估和治疗按预期进行,并且有证据表明接受了治疗 按计划据我们所知,这些将是中风或失语症康复的首批研究之一:(1) 为所有研究成员工作人员纳入多层培训计划,(2)通过以下方式监测治疗保真度 几种互补的方法,以及(3)通过采用既定的治疗方法来监测评估保真度 忠诚准则最后,临床核心还将通过对行为数据进行评分来支持项目, 可靠性测量和结果的盲法测量。因此,核心的主要目标是培训 研究团队,行为数据的评分和管理,以及优化对协议的遵守。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Argye E. Hillis其他文献

Recent advances in the understanding of neglect and anosognosia following right hemisphere stroke
Hypoperfusion regions linked to National Institutes of Health Stroke Scale scores in acute stroke
急性卒中中与美国国立卫生研究院卒中量表评分相关的低灌注区域
  • DOI:
    10.1016/j.nicl.2025.103761
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    3.600
  • 作者:
    Hana Kim;Alex Teghipco;Chris Rorden;Julius Fridriksson;Mathew Chaves;Argye E. Hillis
  • 通讯作者:
    Argye E. Hillis
Surrogate endpoints in clinical trials: ophthalmologic disorders.
临床试验中的替代终点:眼科疾病。
  • DOI:
  • 发表时间:
    1989
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Argye E. Hillis;Daniel Seigel
  • 通讯作者:
    Daniel Seigel
Prolonged venous transit on perfusion imaging is associated with higher odds of mortality in successfully reperfused patients with large vessel occlusion stroke
灌注成像中静脉转运时间延长与成功再灌注的大血管闭塞性卒中患者的较高死亡率相关
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Vivek S. Yedavalli;M. Koneru;M. Hoseinyazdi;Cynthia Greene;D. Lakhani;Risheng Xu;Licia Luna;Justin M Caplan;A. Dmytriw;A. Guenego;J. Heit;Gregory W Albers;Max Wintermark;L. F. Gonzalez;Victor C Urrutia;Judy Huang;K. Nael;Richard Leigh;E. Marsh;Argye E. Hillis;R. Llinas
  • 通讯作者:
    R. Llinas
Follow-up infarct volume on fluid attenuated inversion recovery (FLAIR) imaging in distal medium vessel occlusions: the role of cerebral blood volume index.
远端中血管闭塞中液体衰减反转恢复 (FLAIR) 成像的后续梗塞体积:脑血容量指数的作用。
  • DOI:
    10.1007/s00415-024-12279-3
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Hamza A Salim;Dhairya A. Lakhani;A. Balar;Basel Musmar;Nimer Adeeb;M. Hoseinyazdi;Licia Luna;Francis Deng;Nathan Z Hyson;Janet Mei;A. Dmytriw;A. Guenego;T. Faizy;Jeremy J Heit;Gregory W Albers;Victor C Urrutia;R. Llinas;E. Marsh;Argye E. Hillis;K. Nael;Vivek S. Yedavalli
  • 通讯作者:
    Vivek S. Yedavalli

Argye E. Hillis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Argye E. Hillis', 18)}}的其他基金

Recovery of Affective Prosody after Stroke
中风后情感韵律的恢复
  • 批准号:
    10194446
  • 财政年份:
    2017
  • 资助金额:
    $ 23.31万
  • 项目类别:
Recovery of Affective Prosody after Stroke
中风后情感韵律的恢复
  • 批准号:
    9383116
  • 财政年份:
    2017
  • 资助金额:
    $ 23.31万
  • 项目类别:
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)
艾司西酞普兰和亚急性失语症语言干预 (ELISA)
  • 批准号:
    10094380
  • 财政年份:
    2016
  • 资助金额:
    $ 23.31万
  • 项目类别:
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)
艾司西酞普兰和亚急性失语症语言干预 (ELISA)
  • 批准号:
    10390287
  • 财政年份:
    2016
  • 资助金额:
    $ 23.31万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10390290
  • 财政年份:
    2016
  • 资助金额:
    $ 23.31万
  • 项目类别:
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)
艾司西酞普兰和亚急性失语症语言干预 (ELISA)
  • 批准号:
    10617711
  • 财政年份:
    2016
  • 资助金额:
    $ 23.31万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10094383
  • 财政年份:
    2016
  • 资助金额:
    $ 23.31万
  • 项目类别:
NINDS Research Education Programs for Residents and Fellows in Neurology and Neur
NINDS 针对神经病学和神经病学住院医师和研究员的研究教育计划
  • 批准号:
    8435312
  • 财政年份:
    2009
  • 资助金额:
    $ 23.31万
  • 项目类别:
NINDS Research Education Programs for Residents and Fellows in Neurology and Neur
NINDS 针对神经病学和神经病学住院医师和研究员的研究教育计划
  • 批准号:
    8431804
  • 财政年份:
    2009
  • 资助金额:
    $ 23.31万
  • 项目类别:
NINDS Research Education Programs for Residents and Fellows in Neurology and Neur
NINDS 针对神经病学和神经病学住院医师和研究员的研究教育计划
  • 批准号:
    7778858
  • 财政年份:
    2009
  • 资助金额:
    $ 23.31万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.31万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 23.31万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 23.31万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了